Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023;329:574–87.
Song KW, Lim M, Monje M. Complex neural-immune interactions shape glioma immunotherapy. Immunity. 2025;58:1140–60.
Khan F, Pang L, Dunterman M, Lesniak MS, Heimberger AB, Chen P Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J Clin Invest. 2023;133:e163446.
Zhang Y, He H, Fu X, Liu G, Wang H, Zhong W, et al. Glioblastoma-associated macrophages in glioblastoma: from their function and mechanism to therapeutic advances. Cancer Gene Ther. 2025;32:595–607.
Karimova AF, Khalitova AR, Suezov R, Markov N, Mukhamedshina Y, Rizvanov AA, et al. Immunometabolism of tumor-associated macrophages: a therapeutic perspective. Eur J Cancer. 2025;220:115332.
Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015;42:419–30.
Bae S, Park PSU, Lee Y, Mun SH, Giannopoulou E, Fujii T, et al. MYC-mediated early glycolysis negatively regulates proinflammatory responses by controlling IRF4 in inflammatory macrophages. Cell Rep. 2021;35:109264.
Kureshi CT, Dougan SK. Cytokines in cancer. Cancer Cell. 2025;43:15–35.
Bisht A, Avinash D, Sahu KK, Patel P, Das Gupta G, Kurmi BD. A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. Drug Deliv Transl Res. 2025;15:102–33.
Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 2021;278:119527.
Kciuk M, Gielecińska A, Mujwar S, Kołat D, Kałuzińska-Kołat Ż, Celik I, et al. Doxorubicin-an agent with multiple mechanisms of anticancer activity. Cells 2023;12:659.
Chen S, Saeed A, Liu Q, Jiang Q, Xu H, Xiao GG, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8:207.
Tufail M, Jiang CH, Li N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol Cancer. 2024;23:203.
Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:28.
Kersten K, You R, Liang S, Tharp KM, Pollack J, Weaver VM, et al. Uptake of tumor-derived microparticles induces metabolic reprogramming of macrophages in the early metastatic lung. Cell Rep. 2023;42:112582.
Nicoletto RE, Ofner CM 3rd. Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemother Pharmacol. 2022;89:285–311.
Kopsida M, Clavero AL, Khaled J, Balgoma D, Luna-Marco C, Chowdhury A, et al. Inhibiting the endoplasmic reticulum stress response enhances the effect of doxorubicin by altering the lipid metabolism of liver cancer cells. Mol Metab. 2024;79:101846.
Wang X, Wang Q, Li W, Zhang Q, Jiang Y, Guo D, et al. TFEB-NF-κB inflammatory signaling axis: a novel therapeutic pathway of Dihydrotanshinone I in doxorubicin-induced cardiotoxicity. J Exp Clin Cancer Res. 2020;39:93.
Dreute J, Stengel J, Becher J, van den Borre D, Pfisterer M, Bartkuhn M et al. Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes. Cell Death Differ. 2025;32:2239–56.
El-Sehrawy A, Hsu CY, Alkhathami AG, Chandra M, Basunduwah TS, Malathi H, et al. Metabolic reprogramming: the driving force behind cancer drug resistance. Semin Oncol. 2025;52:152392.
Hu T, Liu CH, Lei M, Zeng Q, Li L, Tang H, et al. Metabolic regulation of the immune system in health and diseases: mechanisms and interventions. Signal Transduct Target Ther. 2024;9:268.
Wang D, Guan H. Glycolytic reprogramming in macrophage polarization: new horizons in the treatment of tumor diseases. Cell Signal. 2025;134:111940.
Makowski L, Chaib M, Rathmell JC. Immunometabolism: From basic mechanisms to translation. Immunol Rev. 2020;295:5–14.
Davuluri GVN, Chan CH. Regulation of intrinsic and extrinsic metabolic pathways in tumour-associated macrophages. Febs j. 2023;290:3040–58.
Chen HJ, Sévin DC, Griffith GR, Vappiani J, Booty LM, van Roomen C, et al. Integrated metabolic-transcriptomic network identifies immunometabolic modulations in human macrophages. Cell Rep. 2024;43:114741.
Certo M, Tsai CH, Pucino V, Ho PC, Mauro C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21:151–61.
Nareika A, He L, Game BA, Slate EH, Sanders JJ, London SD, et al. Sodium lactate increases LPS-stimulated MMP and cytokine expression in U937 histiocytes by enhancing AP-1 and NF-kappaB transcriptional activities. Am J Physiol Endocrinol Metab. 2005;289:E534–42.
Kelly B, O’Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25:771–84.
Song YJ, Kim A, Kim GT, Yu HY, Lee ES, Park MJ, et al. Inhibition of lactate dehydrogenase A suppresses inflammatory response in RAW 264.7 macrophages. Mol Med Rep. 2019;19:629–37.
Hahn EL, Halestrap AP, Gamelli RL. Expression of the lactate transporter MCT1 in macrophages. Shock. 2000;13:253–60.
Li Z, Cui J. Targeting the lactic acid metabolic pathway for antitumor therapy. Mol Ther Oncolytics. 2023;31:100740.
Ziogas A, Novakovic B, Ventriglia L, Galang N, Tran KA, Li W, et al. Long-term histone lactylation connects metabolic and epigenetic rewiring in innate immune memory. Cell. 2025;188:2992–3012.
Cai H, Chen X, Liu Y, Chen Y, Zhong G, Chen X, et al. Lactate activates trained immunity by fueling the tricarboxylic acid cycle and regulating histone lactylation. Nat Commun. 2025;16:3230.
Sun T, Liu B, Cao Y, Li Y, Cai L, Yang W. AMPK-mediated CD47 H3K4 methylation promotes phagocytosis evasion of glioma stem cells post-radiotherapy. Cancer Lett. 2024;583:216605.
